Expanding Sihuan’s Business Reach Overseas

As the Group continues to expand and raise its R&D capabilities, Sihuan Pharmaceutical is extending its reach overseas and exploring deeper, more comprehensive international collaboration.

Domestic and Overseas Layout for a Complete Medical-Aesthetics Portfolio

China’s medical-aesthetics market is growing at more than 20% annually. Aligning with this trend, Sihuan’s Meiyan Space accelerates in-house products through domestic and overseas R&D teams, and brings in high-quality products via strategic partnerships and business development — including leading Korean botulinum toxin and hyaluronic acid, Swiss skin boosters, Korean gold microneedling, and a U.S. fat harvesting system. It has also formed a joint venture with Beijing Bluepha, a synthetic-biology unicorn, to co-develop PHA microspheres and bio-manufactured regenerative materials. Meiyan Space continues to enrich its portfolio across filling, contouring, support, replenishment, energy-based devices, body sculpting, and skincare to meet full life-cycle aesthetic needs.

China–U.S. Dual Filing to Advance Internationalization

Sihuan has entered a strategic partnership with Faron Biotech and will phase in a larger investment in its China-based FDA-certified plant — Guangzhou Foshan Derrico Pharmaceutical. As an international drug R&D and manufacturing platform, the project helps Sihuan gain an early edge in domestic generics development and faster China launches, while laying the foundation for overseas filing, registration, and sales in Europe and the U.S., further advancing the Group’s internationalization.

Innovative R&D Leading the Future

To accelerate innovative-drug programs and reshape competitive dynamics, Sihuan has reviewed, analyzed, and prioritized its pipeline. Beyond existing lines, the Group will focus on areas of major clinical need — including oncology / immuno-oncology, NASH, and diabetes — with emphasis on novel targeted therapies and cancer immunotherapy. Resources are concentrated on nine key Class 1 innovative programs that have already made strong progress. Dozens of generics are also in development, some with clinical approvals, and multiple launches are expected over the next 2–4 years.

Innovative Academic Promotion Driving New Growth

A multi-dimensional sales network spans the country, with more than 3,000 distributors and 600 marketing professionals vigorously advancing national professional academic promotion, scientifically segmenting markets, and unlocking product potential. This distinctive marketing model ensures efficient market operations and fuels Sihuan’s next stage of growth.